PUBLISHER: Nicholas Hall Group of Companies | PRODUCT CODE: 1111225
PUBLISHER: Nicholas Hall Group of Companies | PRODUCT CODE: 1111225
As the global retail market returns to high growth in 2021-22, bouncing back from an historic and coronavirus-driven decline, Analgesics is among the fastest-growing major categories. What are the factors behind this growth and how sustainable are they?
Systemic analgesics have undoubtedly benefited from recommendations for OTC products to treat fever and pain following Covid-19 vaccinations, while resurgence of cold & flu infections has particularly bolstered the children's pain segment. Topical analgesics profited from a post-lockdown return to active lifestyles and corresponding increase in exercise-related pain. Indeed a pandemic-driven shift in lifestyle routines (sedentary habits, increased screen use, stress and shifting sleep patterns) helped drive sales of all pain relief brands.
Meanwhile, Switch has expanded categories in certain markets and NPD fortified selected brands, while several marketers enjoyed success by targeting specific pain niches. Strong A+P investment, as marketer confidence returns, has proved an important growth driver in some areas.
How will marketers take advantage of these new trends? Where can they look for sustained growth or expand their offerings to exploit new niches? What is the next development that helps create dynamism in a mature market?
|
|
By examining 12 core markets in fine detail, analysing brand performances, segment growth and launch activity, our latest Analgesics Report aims to investigate the untapped potential in this dynamic CHC category.
The report features the latest MAT Q2 2022 sales data from our dedicated DB6 database, including topline historical sales globally, by country and category, as well as individual brand performances, and long-term forecasts to 2026 and 2031.
Diving into the factors affecting the Analgesics market, from consumer trends and regulatory changes to A+P campaigns and new product launch activity, this report sheds light on trends & developments across 12 in-depth country profiles (generating 70% of global sales between them) with insights and predictions.
Data analysis within each country profile includes a breakdown of 2021 sales by key ingredient in Systemic analgesics and Topical analgesics. Systemics sales are also divided into adult and children's presentations, while Topicals sales are split by format and medicated vs non-medicated presentations.
The important adjacent category of herbal & natural joint health supplements, where new ingredients are gaining favour, is also investigated.
Assessing the short-term outlook, the report also includes full-year 2022 & 2023 category-level analgesics forecasts in each market profiled.
†sales tracked under VMS in DB6.
With a high degree of launch activity among analgesics, new product development is explored across markets. Brand case studies evaluate the key lessons to be learned from top brands, including consumer messaging, line extensions, portfolio development and brand strategies.
The most interesting developments in recent scientific research are rounded up, with a look at promising new ingredients and benefits, while CBD's role in pain relief is also examined.